General discussion, page-265

I’ve been a shareholder for a number of years and have a very different view than you, in fact it’s chalk & cheese. I can’t understand how you could come to the view that you stated, albeit a “one liner”.

The following is evidence of “walk”...

- 4 clinical trials about to commence
- Trials paid by Cannvalate, very modest cost to IHL
- Strong balance sheet, no debt
- Revenue growing from CBD oils sales and connected to the largest script provider in Australia
- Management with significant equity and so aligned to shareholders
- Dr Agarwal with performance milestones that are aligned to shareholders

Hopefully you find another winner. Probably need to buy a bell as well.